Mar. 19 at 2:11 AM
$GERN When I phrased the question differently, another answer came up:
"Yes, if imetelstat (branded as RYTELO) is advanced into a pill or oral form, Geron Corporation would likely receive financial benefits through their existing intellectual property, provided those patents are still active or applicable to the new formulation.
Patent Coverage: Geron holds multiple patents related to imetelstat, including composition of matter patents (expiring Dec 2025) and method of use patents (expiring in 2033 or later). Any oral formulation would likely still use the same active compound (imetelstat sodium) or method of action, which is protected ... Because Geron owns RYTELO exclusively, any new form developed (even if by a future partner) would be under a new licensing deal, which would include royalties or milestones for Geron ... However, it is important to note that the composition of matter patent is set to expire in December 2025, while method-of-use patents extend to 2033."
